What is NDC 72893-016?

72893-016 is the product NDC for Ryzneuta (efbemalenograstim alfa-vuxw), Efbemalenograstim alfa 20 mg/mL injection, listed with the FDA by Acrotech Biopharma Inc. It has 1 package NDC, shown above in 10- and 11-digit form.

What drug is associated with this NDC?

Ryzneuta (Efbemalenograstim alfa-vuxw).

Acrotech Biopharma Inc, NDC labeler code 72893. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Ryzneuta?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Ryzneuta NDC 72893-016 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)72893-016Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72893-0016Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72893-016-02	7289300160272893001602	1 SYRINGE in 1 CARTON (72893-016-02) / 1 mL in 1 SYRINGEMarketed from Nov 23, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Ryzneuta
Generic name (nonproprietary): efbemalenograstim alfa-vuxw
Active ingredients: Efbemalenograstim alfa — 20 mg/mL
Dosage form: Injection
Route: Subcutaneous
Labeler: Acrotech Biopharma IncNDC labeler code 72893
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 761134
Marketing start: Nov 23, 2023
Listing expires: Dec 31, 2027
Other FDA classes: Colony-Stimulating Factors (Chemical structure)
Identifiers: Product ID 72893-016_523867f4-dbc4-1258-e063-6394a90a3145SPL ID 523867f4-dbc4-1258-e063-6394a90a3145SPL set ID 290ed754-758c-9cae-e063-6294a90ae68bRxCUI 2670662, 2670669UNII 5UPW5HJW3O
Pharmacologic class: Leukocyte Growth Factor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N472893001602 followed by a unit qualifier and the quantity

Package 72893-0016-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 19, 2026.

Indications (excerpt from the label)

1. INDICATIONS AND USAGE RYZNEUTA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Limitations of Use RYZNEUTA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. RYZNEUTA is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 72893-016

What is NDC 72893-016?: 72893-016 is the product NDC for Ryzneuta (efbemalenograstim alfa-vuxw), Efbemalenograstim alfa 20 mg/mL injection, listed with the FDA by Acrotech Biopharma Inc. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Ryzneuta (Efbemalenograstim alfa-vuxw).
What is the active ingredient?: Efbemalenograstim alfa.
Who is the labeler?: Acrotech Biopharma Inc, NDC labeler code 72893. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Ryzneuta?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Ryzneuta (Efbemalenograstim alfa-vuxw) NDC 72893-016